Entity

Time filter

Source Type


Shirai T.,Tokai University | Suzuki Y.,Tokai University | Suzuki Y.,Nichinichi Pharmaceutical Corporation Ltd | Kamikado K.,Tokai University | And 4 more authors.
International Journal of Probiotics and Prebiotics | Year: 2013

Kestose, a prebiotic fructooligosaccharide, has been shown to exert a therapeutic effect on the clinical manifestation of atopic dermatitis (AD) in infants through a unknown mechanisms. Since restoration of the impaired intestinal barrier may be useful for the treatment of AD, we investigated the effect of kestose on the intestinal barrier using the Caco-2 cell monolayer in a Ca2+ switch assay. Our results show that apical kestose treatment (1% w/v) led a significant acceleration of the restoration of barrier function after Ca2+ replenishment. Kestose also enhanced the reassembly of tight junction (TJ) proteins. An acceleration in the deposphorylation of myosin light chain (MLC) was also found by kestose treatment. Moreover, an inhibitor of Rho-associated kinase (ROCK), a key enzyme involved in the phosphorylation of MLC, abrogated the kestose-mediated promotion of TJ restoration. These results indicate that kestose accelerates the recovery of epithelial TJ assembly through the induction of MLC dephosphorylation via a ROCK-dependent mechanism. Copyright © 2013 by New Century Health Publishers, LLC.


Patent
Tokai Medical Test Laboratory Co., B Food Science Co. and NichiNichi Pharmaceutical Co. | Date: 2011-02-22

Disclosed is a composition containing a specific oligosaccharide and a bivalent metal cation, which exhibits an effect on the amelioration, treatment or prevention of allergy or topical inflammatory reactions in an extremely safe and effective manner compared to synthetic oral steroid medicines in spite of a fact that the composition contains components that are generally familiar as a food or an ion occurring in living bodies and have no toxicity against living bodies when used at physiological concentrations. Specifically disclosed is a cell-cell adhesion enhancer in epithelial cells, which comprises 1-kestose and/or nystose and a bivalent metal cation as active ingredients. The enhancer can prevent the disruption of an epithelial cell-cell tight junction protein that causes the invasion of an allergen into the body, can repair the epithelial cell-cell tight junction protein or promote the formation of the epithelial cell-cell tight junction protein, whereby the epithelial cell-cell adhesion can be enhanced and the effective amelioration, treatment and prevention of allergic symptoms can be achieved.


Takashi S.,Nichinichi Pharmaceutical Corporation Ltd | Mariko O.,Nichinichi Pharmaceutical Corporation Ltd | Kazutake F.,Nichinichi Pharmaceutical Corporation Ltd | Atsushi H.,Nichinichi Pharmaceutical Corporation Ltd | And 2 more authors.
Nippon Shokuhin Kagaku Kogaku Kaishi | Year: 2011

We established an allergic model of the late phase of type I hypersensitivity reaction to cedar pollen in mice. In this model, BALB/c mice (5-week-old females) were immunized five times with cedar pollen allergen, and eosinophil accumulation in the peritoneal cavity was elicited by an intraperitoneal injection of the allergen. We investigated the effects of the leaf of Moringa oleifera on allergen-induced eosinophil accumulation and total IgE in serum by giving freely feeding mice a powder diet containing 0.3%, 1.0%, and 3.0% M. odeifera leaf powder. Compared to the control group (normal diet), the number of total leukocytes and eosinophils accumulated in the peritoneal cavity was significantly reduced in the groups given the diet containing 0.3% and 3.0% M. oleifera leaf powder. However, there were no differences in the number of lymphocytes, monocytes, and neutrophils between all groups. Furthermore, the serum level of total IgE was reduced in the M. oleifera leaf powder-treated groups. These results provide laboratory evidence that M. oleifera leaf powder reduces eosinophil accumulation at the site of allergic inflammation and attenuates the development of IgEmediated allergy.


Shimada T.,Nichinichi Pharmaceutical Corporation Ltd | Shimada T.,Nanjing Medical University | Kondoh M.,Nichinichi Pharmaceutical Corporation Ltd | Motonaga C.,Nichinichi Pharmaceutical Corporation Ltd | And 7 more authors.
Asian Pacific Journal of Allergy and Immunology | Year: 2010

Kampo is a traditional Japanese medicine originating from ancient Chinese medicine which included the administration of herbal prescription, lifestyle advice and acupuncture. Orally administered Kampo prescriptions are believed to be influenced by diet and intestinal microbiota. However, reports on the Kampo administration effects are still limited. Shoseiryuto (TJ-19), which has anti-allergic and anti-inflammatory properties, is a Kampo prescription used clinically for the treatment of allergic bronchial asthma. We examined whether Shoseiryuto administration is affected by a probiotic product, lysed Enterococcus faecalis FK-23 (LFK). BALB/c mice were sensitized with cedar pollen allergen, and the peritoneal accumulation of eosinophils was induced. During a sensitization period of 21 days, varying amounts of Shoseiryuto (and saline as a control) were administered to the mice. The accumulation of eosinophils was significantly reduced by 30 mg/day doses of Shoseiryuto but not by 3 or 9 mg/day doses. Similarly, 3 mg/day Shoseiryuto, 30 mg/day LFK, 3 mg/day of Shoseiryuto co-administered with 30 mg/day of LFK, and saline control were compared. A significant reduction in the accumulation of eosinophils was observed at 3 mg/day Shoseiryuto co-administered with 30 mg/day of LFK. These results suggest that Shoseiryutomediated anti-allergic effects are enhanced by the probiotic (LFK). Although not significant statistically, serum allergen-specific and total IgE levels in the treatment group exposed to the mixed agent (i.e. Shoseiryuto and LFK) were generally lower than those receiving either one alone. The results indicate a synergistic effect of a Kampo medicine (Shoseiryuto, Xiao-Qing-Long-Tang in Chinese) and lysed Enterococcus faecalis FK-23 on allergic responses in mice.


Kondoh M.,Nichinichi Pharmaceutical Corporation Ltd | Kondoh M.,Kyoto Prefectural University of Medicine | Shimada T.,Nichinichi Pharmaceutical Corporation Ltd | Shimada T.,Kyoto Prefectural University of Medicine | And 9 more authors.
British Journal of Nutrition | Year: 2014

A high-fat diet (HFD) is one of the causes of hepatic steatosis. We previously demonstrated that Enterococcus faecalis FK-23 (FK-23), a type of lactic acid bacteria, exhibits an anti-obesity effect in mice fed a HFD. In the present study, we examined the effects of FK-23 on HFD-induced hepatic steatosis. Male C57BL/6 mice were divided into four groups and given one of four treatments: standard diet (SD); standard diet supplemented with FK-23 (SD+FK); HFD; or HFD supplemented with FK-23 (HFD+FK). For the administration of FK-23, the drinking water was supplemented with FK-23 at a concentration of 2% (w/w). After 11 weeks, histological findings revealed hepatic steatosis in the liver of HFD-fed mice; however, this effect was attenuated by the administration of FK-23. The expression levels of genes involved in fatty acid oxidation in the liver tissue were significantly reduced in the HFD group compared with the SD group, but FK-23 supplementation tended to up-regulate the expression levels of these genes. Our findings show that the inhibitory effect of FK-23 against hepatic steatosis in HFD-fed mice can be explained by the prevention of fat accumulation in the liver through the modulation of the activities of genes involved in hepatic fatty acid oxidation. Copyright © 2014 The Authors.

Discover hidden collaborations